CL2019002218A1 - Formulaciones de combinación triple y métodos para tratar o reducir el riesgo de enfermedad cardiovascular. - Google Patents

Formulaciones de combinación triple y métodos para tratar o reducir el riesgo de enfermedad cardiovascular.

Info

Publication number
CL2019002218A1
CL2019002218A1 CL2019002218A CL2019002218A CL2019002218A1 CL 2019002218 A1 CL2019002218 A1 CL 2019002218A1 CL 2019002218 A CL2019002218 A CL 2019002218A CL 2019002218 A CL2019002218 A CL 2019002218A CL 2019002218 A1 CL2019002218 A1 CL 2019002218A1
Authority
CL
Chile
Prior art keywords
treat
risk
reduce
cardiovascular disease
methods
Prior art date
Application number
CL2019002218A
Other languages
English (en)
Inventor
Narendra Lalwani
Diane Macdougall
Original Assignee
Esperion Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Esperion Therapeutics Inc filed Critical Esperion Therapeutics Inc
Publication of CL2019002218A1 publication Critical patent/CL2019002218A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

MÉTODO PARA TRATAR O REDUCIR EL RIESGO DE ENFERMEDAD CARDIOVASCULAR QUE COMPRENDE ADMINISTRAR ETC-1002, EZETIMIBE Y UNA ESTATINA; FORMULACIÓN FARMACÉUTICA QUE COMPRENDE A ETC-1002, EZETIMIBE, UNA ESTATINA Y EXCIPIENTES; Y KIT QUE COMPRENDE A LA COMPOSICIÓN.
CL2019002218A 2017-02-08 2019-08-06 Formulaciones de combinación triple y métodos para tratar o reducir el riesgo de enfermedad cardiovascular. CL2019002218A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762456571P 2017-02-08 2017-02-08

Publications (1)

Publication Number Publication Date
CL2019002218A1 true CL2019002218A1 (es) 2020-02-21

Family

ID=63107115

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2019002218A CL2019002218A1 (es) 2017-02-08 2019-08-06 Formulaciones de combinación triple y métodos para tratar o reducir el riesgo de enfermedad cardiovascular.
CL2021002447A CL2021002447A1 (es) 2017-02-08 2021-09-21 (divisional de solicitud 2218-2019) formulaciones de combinación triple y métodos para tratar o reducir el riesgo de enfermedad cardiovascular.

Family Applications After (1)

Application Number Title Priority Date Filing Date
CL2021002447A CL2021002447A1 (es) 2017-02-08 2021-09-21 (divisional de solicitud 2218-2019) formulaciones de combinación triple y métodos para tratar o reducir el riesgo de enfermedad cardiovascular.

Country Status (9)

Country Link
US (1) US20210361618A1 (es)
EP (1) EP3579827A4 (es)
JP (2) JP2020506241A (es)
CN (1) CN110536684A (es)
BR (1) BR112019016307A2 (es)
CL (2) CL2019002218A1 (es)
IL (1) IL268502A (es)
MX (1) MX2019009418A (es)
WO (1) WO2018148417A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102370582B1 (ko) 2015-03-13 2022-03-04 에스페리온 테라피유틱스 인코포레이티드 Ｅｔｃ1002 및 에제티미브를 포함하는 고정 용량 조합 및 제형 및 심혈관 질환의 치료 또는 이의 위험의 감소 방법
JP2020506241A (ja) 2017-02-08 2020-02-27 エスペリオン・セラピューティクス・インコーポレイテッドＥｓｐｅｒｉｏｎ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． トリプレット組み合わせ製剤、及び心血管疾患を治療又はそのリスクを低下させる方法
JP2021534208A (ja) * 2018-08-24 2021-12-09 エスペリオン・セラピューティクス・インコーポレイテッドEsperion Therapeutics, Inc. 高コレステロール関連疾患について処置されている患者において糖尿病のリスクを低減させる方法
EP3844168A4 (en) * 2018-08-27 2022-05-18 Esperion Therapeutics, Inc. COMBINATION DRUG PREPARATIONS FOR THE TREATMENT OF PATIENTS WITH CARDIOVASCULAR DISEASE AND ASSOCIATED CONDITIONS
WO2020213010A1 (en) 2019-04-16 2020-10-22 Celagenex Research (India) Pvt. Ltd. Synergistic lipid controlling compositions
US20230141635A1 (en) 2019-06-21 2023-05-11 Esperion Therapeutics, Inc. Salt forms of bempedoic acid and methods for using the same
CN113133997B (zh) * 2020-01-20 2024-02-09 深圳市长卿医学研究院 一种含小檗碱的药物组合物及其用途
CN113134086B (zh) * 2020-01-20 2024-05-24 深圳市长卿医学研究院 一种降血脂的药物组合物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006109170A2 (en) * 2005-04-14 2006-10-19 Esperion Therapeutics Inc. Combination therapy for treatment of cardiovascular diseases and related conditions
MX367352B (es) * 2012-01-06 2019-08-16 Gemphire Therapeutics Inc Metodos para reducir el riesgo de padecer una enfermedad cardiovascular.
US9255154B2 (en) * 2012-05-08 2016-02-09 Alderbio Holdings, Llc Anti-PCSK9 antibodies and use thereof
GB201318793D0 (en) * 2013-10-24 2013-12-11 Plaquetec Ltd Vascular Biomarkers
KR102370582B1 (ko) * 2015-03-13 2022-03-04 에스페리온 테라피유틱스 인코포레이티드 Ｅｔｃ1002 및 에제티미브를 포함하는 고정 용량 조합 및 제형 및 심혈관 질환의 치료 또는 이의 위험의 감소 방법
MA41793A (fr) * 2015-03-16 2018-01-23 Esperion Therapeutics Inc Associations de doses fixes comprenant du etc1002 et une ou plusieurs statines permettant de traiter ou de réduire un risque cardiovasculaire
JP2020506241A (ja) 2017-02-08 2020-02-27 エスペリオン・セラピューティクス・インコーポレイテッドＥｓｐｅｒｉｏｎ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． トリプレット組み合わせ製剤、及び心血管疾患を治療又はそのリスクを低下させる方法

Also Published As

Publication number Publication date
WO2018148417A1 (en) 2018-08-16
JP2020506241A (ja) 2020-02-27
EP3579827A4 (en) 2021-01-06
CN110536684A (zh) 2019-12-03
CL2021002447A1 (es) 2022-04-22
US20210361618A1 (en) 2021-11-25
BR112019016307A2 (pt) 2020-03-31
IL268502A (en) 2019-09-26
MX2019009418A (es) 2019-10-02
JP2023040237A (ja) 2023-03-22
EP3579827A1 (en) 2019-12-18

Similar Documents

Publication Publication Date Title
CL2019002218A1 (es) Formulaciones de combinación triple y métodos para tratar o reducir el riesgo de enfermedad cardiovascular.
PE20191474A1 (es) Compuestos de amino-triazolopiridina y su uso en el tratamiento del cancer
EA201892395A1 (ru) Лекарственные составы ингибитора lsd1
CL2016002516A1 (es) “compuestos derivados de espirociclo sustituidos, inhibidores atx; composición farmacéutica que los comprende; y su uso en el tratamiento del cáncer, inflamaciones, dolor neuropático, enfermedades fibróticas, trombosis, entre otros”. pct
BR112016020199A8 (pt) composto inibidor de calicreína plasmática de humano, composição farmacêutica compreendendo o referido composto, kit e seu uso
AR091876A1 (es) Combinaciones farmaceuticas para el tratamiento de enfermedades proliferativas
CL2019001996A1 (es) Usos terapéuticos de un polvo de insectos.
GT201700179A (es) Formulaciones en polvo nasal para el tratamiento de hipoglicemia
CL2017002334A1 (es) Combinaciones y formulaciones de dosis fijas que comprenden etc-1002 y una o más estatinas y métodos para tratar o reducir el riesgo de enfermedad cardiovascular
BR112018005905A2 (pt) ?composto, composição farmacêutica, métodos para evitar ou tratar uma doença ou condição, lesões de órgão, hepatotoxicidade e fígado gorduroso, e, uso de um composto?
DOP2016000254A (es) Formulaciones farmeceuticas de inhibidor de la quinasa pan-raf, procedimientos para su preparacion, y metodos de uso.
PH12019502150A1 (en) Compounds and methods for the treatment of parasitic diseases
BR112018015367A2 (pt) carreadores oromucosais de nanofibra para tratamento terapêutico
CR20180080A (es) Combinaciones de un anticuerpo ox40 y un modulador de tlr4 y usos de las mismas
ECSP16086247A (es) (s)-pirlindole y sus sales farmacéuticamente aceptables para uso en medicina
CL2021000924A1 (es) Uso de reboxetina para el tratamiento de narcolepsia
BR112021000279A8 (pt) formulações de redução de tumor e métodos de uso das mesmas
CL2019002480A1 (es) Derivados de pirazol como inhibidores de bromodominio.
BR112018014723A2 (pt) fantasmas bacterianos para o tratamento de câncer
MX2020004513A (es) Cocristales, composiciones farmacéuticas de los mismos y métodos de tratamiento que los implican.
BR112018074655A2 (pt) formulação injetável de fosnetupitant e método de fabricação de uma formulação
CL2019003288A1 (es) Una combinación farmacéutica para el tratamiento de un cáncer.
CL2020000586A1 (es) Moduladores de la expresión de enac.
CO2019007671A2 (es) Una composición farmacéutica que comprende un derivado de oxazina y su uso en el tratamiento o la prevención de la enfermedad de alzheimer
AR103636A1 (es) Métodos de tratamiento de neuralgia postherpética con una formulación tópica de un compuesto de espiro-oxindol